CenExel JBR
Murray, Utah, 84107, United States
NCT Number: NCT06241742
The goal of this clinical trial is to test the ability of HT-6184 to decrease inflammation and pain in patients after third molar removal.
The main question it aims to answer are:
* Does HT-6184 decrease inflammation in patients after third molar removal? * Does HT-6184 decrease pain in patients after third molar removal?
Participants will be asked to do the following during the clinical trial:
* Take a single oral dose of HT-6184 or placebo * Allow a oral surgeon remove their third molar teeth * Blood draws on 5 occurrences * Rate their pain intensity * Attend two follow-up appointments on day 1 and day 2 after third molar removal * Participate in one follow-up phone call 5-7 days after third molar removal
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 2
Murray, Utah, 84107, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Single, oral dose of HT-6184
Single, oral dose of placebo
Time frame: Up to 54 hours post surgery
Time frame: Up to 7 days post surgery
Severity of AEs will be judged according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
Time frame: Up to 7 days post surgery
Severity of AEs will be judged according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
Time frame: Up to 8 hours after surgery
Halia Therapeutics, Inc.
Industry
A Phase-2 Study to Evaluate the Ability of HT-6184 to Attenuate Diagnostic Biomarkers of Post-procedure Acute Inflammation and Manage Pain Following Third Molar Extraction
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07196904
Impacted Mandibular Third Molar, Inflammation
Ho Chi Minh City, Vietnam
View Trial DetailsNCT03083548
Arthritis, Image, Body
Oslo, Norway
View Trial DetailsNCT07092215
Hyperalgesia, Inflammation
Vienna, State of Vienna, Austria
View Trial DetailsNCT06041425
Adenocarcinoma, Carcinoma
Nanjing, Jiangsu, China
View Trial Details